DELRAY BEACH, Fla., Oct. 5, 2026 /PRNewswire/ -- Vehere Inc, is an AI cybersecurity and network intelligence company, specializing in AI-powered cyber network intelligence and advanced cyber defense solutions, has been recognized as a Progressive Player in the Network Detection and Response NDR market by the MarketsandMarkets™ 360Quadrants platform.

Vehere Technologies helps organizations improve network visibility, threat detection, and cyber defense through its Network Detection and Response portfolio. The company combines expertise developed in defense and intelligence environments with enterprise cybersecurity capabilities, providing solutions for network detection and response, network forensics, national cyber defense, and lawful interception.

Vehere NDR combines AI/ML-based behavioral analysis, continuous packet capture, threat intelligence, network forensics, and threat hunting to detect and investigate cyber threats. Designed for enterprise and large-scale networks, Vehere helps security teams identify suspicious activity, investigate threats, and respond to security incidents faster.

A key aspect of Vehere NDR is its focus on deep network visibility and large-scale analysis. The platform is designed for high-throughput environments and provides organizations with greater control over network data while supporting real-time detection and investigation. This makes Vehere NDR relevant for organizations that require scalable network monitoring, advanced threat detection, detailed forensics, and proactive threat hunting.

Vehere NDR is designed not only to respond to alerts but also to allow security teams to actively search for threats. Its threat-hunting capabilities include - Historical and real-time network hunting, Behavioral threat discovery, Supervised and unsupervised ML, Large-scale IOC searching, Retrospective examination and Detection of stealthy or previously unknown activity.

A major capability of Vehere NDR is analysis of encrypted network activity. Vehere uses TLS fingerprints such as JA3, JA3S and JA4, along with handshake metadata, packet sizes, flow behavior and beaconing patterns. Vehere NDR is designed to work with an organization's existing security ecosystem. The platform supports integration with SIEM, SOAR, EDR/XDR, firewalls, threat-intelligence platforms, ITSM, identity systems and other technologies. Its integration framework supports technologies such as REST APIs, Syslog, STIX/TAXII, Webhooks, SMTP, SNMP and LDAP/Active Directory.

The Vehere SIGINT is a national-scale cyber intelligence and Network Detection and Response (NDR) platform, designed for governments, national CERTs/CSIRTs, cyber command teams, and national SOCs that need visibility across large parts of a country's digital infrastructure. Vehere National NDR supports real-time situational awareness, incident investigation, containment, and emergency response. The platform can help analysts reconstruct sessions, identify compromised systems and investigate the incident using network evidence.

Vehere SIGINT specifically identifies critical infrastructure protection as a use case. The platform is intended to help monitor sectors such as Energy, Transportation, Finance, Telecommunications, Government infrastructure and Other nationally important digital systems. The objective is to detect and respond to cyber intrusions before they can spread or cause significant disruption.

Vehere Technologies differentiates its NDR offering by combining deep packet-level network visibility, AI/ML-based threat detection, advanced network forensics, and proactive threat hunting within a scalable platform. Its ability to support 100% lossless packet capture, petabyte-scale data, 5,000+ protocols, encrypted-traffic analysis, dynamic file analysis, and retrospective investigation provide security teams with detailed network evidence for detecting and investigating sophisticated threats.

Beyond enterprise NDR, Vehere also extends its capabilities to national-scale cyber defense, supporting governments and cyber security organizations with large-scale network intelligence and situational awareness. This combination of network visibility, intelligent detection, forensic investigation, and scalable cyber defense represents a key differentiating aspect of Vehere's technology portfolio.

Methodology

360Quadrants provides an in-depth evaluation and comparison of each key market player based on various techno-commercial inputs provided by industry experts, customers, vendors, and other stakeholders, along with secondary research that includes product brochures, analyst notes, company publications, business articles, white papers, trade sources, and various other databases.

A well-defined methodology is adopted to provide detailed ratings for each market player concerning various parameters as outlined below:

- Shortlisting of 25+ prominent market players & start-ups

- Relevant portfolio mapping at the regional level

- Key growth initiatives undertaken at the regional level

- Revenue analysis at a regional and category level

- Strategic collaborations with governments, patient/customer groups, etc.

- Other industry-relevant parameters

About 360Quadrants

360Quadrants is the largest marketplace looking to disrupt over USD 3.7 trillion of technology spend and is the only rating platform for vendors in the technology space. The platform provides users with unbiased information that helps them make informed business decisions, while also enabling vendors to influence the business decisions of potential clients. Vendors get to win ideal new customers, customize their quadrants, decide key parameters, and position themselves strategically in a niche space, to be consumed by giants and start-ups alike. Experts grow their brands and increase their thought leadership. The platform targets the building of a social network that links industry experts with companies worldwide.

360Quadrants has also launched quadrants in fields like Fraud Detection and Prevention (FDP) Market, Endpoint Security Market, and Cloud Security Market.

About MarketsandMarkets:

MarketsandMarkets™, recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report, is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With a broad lens on emerging technologies, the company is proficient in co-creating exceptional growth for clients worldwide.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust it to accelerate their revenue growth. With a global clientele of over 13,000 organizations, MarketsandMarkets helps businesses thrive in a rapidly evolving and disruptive ecosystem.

The B2B economy is witnessing the emergence of USD 25 trillion in new revenue streams that are replacing existing ones within this decade. MarketsandMarkets collaborates with clients on growth programs, enabling them to monetize this USD 25 trillion opportunity through their service lines, including TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, MarketsandMarkets collaborates with several Forbes Global 2000 B2B companies to keep them future-ready. The company's insights and strategies are powered by industry experts, cutting-edge AI, and their proprietary Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit https://www.marketsandmarkets.com/ or follow them on Twitter, LinkedIn, and Facebook.

Contact:

Ms. Sipti Banga,

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

SOURCE MarketsandMarkets

Share this article

Bringing five-day world-class basketball event to Oct. 7-11 Advancing tourism and sport synergies Driving Macao's economic diversification

MACAO, Oct. 5, 2026 /PRNewswire/ -- Sands China has long been committed to supporting the Macao SAR government's policy of promoting economic diversification –– by leveraging its extensive international network and integrated resort platforms to bring world-class sporting events to Macao, thereby helping reinforce the city's position as a World Centre of Tourism and Leisure. After drawing an enthusiastic response from audiences in Macao and around the world during its debut last year, The NBA China Games returns this year with two preseason games, Oct. 9 and 11 at The Venetian Arena of The Venetian® Macao, featuring a Texas matchup between the Dallas Mavericks and the Houston Rockets.

To further amplify the synergies between tourism and sports, Sands China and the National Basketball Association (NBA) are presenting a series of activities alongside the games. These include NBA Fan Day, taking place at The Venetian Arena on Oct. 10, featuring appearances and interactions with NBA players and performances by popular Asian artists, offering fans an up-close experience of the energy and excitement of the NBA; NBA HOUSE, open to the public free of charge at Halls A and B of Cotai Expo at The Venetian Macao from Oct. 7 to 11, bringing together basketball, music and entertainment, fashion and retail, interactive technology, and specialty dining offerings in a five-day festival for residents and visitors; and the five-day "NBA Cares x Sands Cares Community Impact Week," running from Oct. 7 to 11 at locations across the Macao community, extending the world-class basketball event to the community and school, engaging a broader cross-section of local society.

Together, these exciting offerings will help further elevate Macao's reputation as a premier city destination for mega events, while strengthening its status as a "City of Sports" and injecting fresh momentum into the city's economic diversification.

The NBA China Games 2026 | Two Preseason Games Set to Take the Court

The NBA China Games 2026 will feature two preseason games between the Dallas Mavericks and the Houston Rockets at The Venetian Arena, with the first game set to take place at 7:30 p.m. on Friday, Oct. 9, and the second at 5:30 p.m. on Sunday, Oct. 11.

The Mavericks currently feature 2016 NBA champion and nine-time NBA All-Star Kyrie Irving, 2025-26 NBA Rookie of the Year Cooper Flagg, and 2026 No. 9 overall pick Morez Johnson Jr. The Rockets currently feature two-time NBA champion and 16-time NBA All-Star Kevin Durant, two-time NBA All-Star Alperen Sengun, and 2024-25 NBA All-Defensive First Team member Amen Thompson.

Adding to the excitement on game day, South Korean Gen Z girl group KiiiKiii will take the stage during halftime, bringing dynamic performances and youthful energy that are sure to electrify the arena.

NBA Fan Day | Star-studded Asian Line-up to Deliver an Unforgettable Fan Experience

NBA Fan Day will be at The Venetian Arena at 3:30 p.m. on Oct. 10, featuring a line-up of artists from across Asia. Performers will include K-pop star EVAN, also known as HEESEUNG, and Hong Kong singer-actor and MIRROR member Keung To, with rapper-actor MC Jin serving as host. Live performances will keep the energy high throughout the event, immersing audiences in the thrill of NBA basketball.

The event will offer a variety of fan engagement activities, featuring Mavericks and Rockets players, entertainment and mascots. Highlights include a skills challenge, three-point contest, shooting stars challenge, and a slam dunk show featuring professional dunkers –– giving fans the opportunity to experience the energy of NBA basketball up close.

NBA HOUSE | An Expanded One-stop NBA Basketball Carnival

Intensifying the liveliness, the expanded edition of NBA HOUSE Macao 2026 is coming Oct. 7-11 to Halls A and B of The Venetian Macao's Cotai Expo. The five-day experience is open to the public free of charge from 11 a.m. to 10 p.m. each day. As a major fan engagement platform for The NBA China Games 2026, this year's edition gathers nearly 30 renowned global brand partners and exhibitors, creating a one-stop, vibrant basketball carnival featuring specialty dining, music and entertainment, fashion and retail, interactive technology and party experiences. The event will extend the momentum of the games to the broader community while further enriching Macao's sports tourism offering.

NBA HOUSE will feature an extensive programme of activities, with NBA legends Ray Allen, Carlos Boozer, Chris Bosh, Jeremy Lin, Stephon Marbury, Shawn Marion, Cuttino Mobley, Mitch Richmond, Luis Scola, and P.J. Tucker, along with Chinese basketball star Ding Yanyuhang, headlining the event and interacting with fans on-site, giving the public the opportunity to meet some of basketball's legendary figures in person.

In addition, Asian stars KiiiKiii and SB19 will deliver electrifying performances, while EVAN and MIRROR member Keung To will make special appearances for live performances, bringing added star power and further elevating the pulsating atmosphere at NBA HOUSE.

The venue will feature a range of interactive experiences and exhibition zones, including exclusive themed zones dedicated to the Mavericks and the Rockets, photo opportunities with NBA trophies on display, and "NBA Inside the Game powered by AWS" – an interactive shooting experience on a smart digital LED court.

The newly upgraded Merchandise Village will also return to NBA HOUSE this year, bringing together the NBA Store, NBA Atelier, and merchandise from the two participating teams and a range of official partners at Halls A and B of The Venetian Macao's Cotai Expo. Fans can explore an extensive selection of official NBA products, collectibles and lifestyle apparel, including a customization lab. Another highlight will be the expanded themed food and beverage area, which will cover more than 1,500 square metres and combine local favourites with authentic Texas cuisine, offering fans a flavourful and diverse dining experience.

Two viewing parties will also be held during the event, where fans can get together to enjoy the world-class basketball matches in a lively atmosphere.

"NBA Cares x Sands Cares Community Impact Week" | Exemplifying Sands Cares Spirit

Co-organised by Sands China's Sands Cares programme and NBA Cares, the "NBA Cares x Sands Cares Community Impact Week 2026" will take place Oct. 7-11. Featuring five themed activities, namely Youth Day, Tip-off, School Day, Health and Wellness Day, and the Community Basketball Carnival, the initiative takes NBA legends and current players to visit local communities, providing Macao residents of all ages and backgrounds with valuable opportunities to learn, interact and be inspired.

By bringing a world-class basketball event into the local community, the Impact Week aims to inspire positive youth development, foster social inclusion and promote greater awareness of physical and mental well-being. Through these meaningful outreach activities, it seeks to champion the values of care, healthy living and sportsmanship.

With broad participation from across the community, the Impact Week fully demonstrates Sands China's longstanding commitment to the spirit of Sands Cares and its dedication to growing alongside and serving the Macao community. By harnessing the synergies arising from major sports tourism events, the initiative not only supports Macao's economic diversification, but also unites charitable efforts from across regions to foster a more caring and inclusive community in Macao, while demonstrating the vitality and impact of Macao's "Tourism+" strategy.

For the latest arrangements for The NBA China Games 2026 and related events, as well as registration information for selected performances, please visit NBAChinaGames.com. Macao residents, visitors and basketball fans alike are invited to join the vibrant line-up of activities and experience this spectacular celebration that blends basketball, entertainment, tourism and leisure, and community engagement.

About Sands China Ltd. Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian® Macao, The Plaza® Macao, The Parisian® Macao and The Londoner® Macao. The Company also owns and operates Sands® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

Share this article

PRO SHOP RAISES $24 MILLION SERIES B TO ACCELERATE NEXT PHASE OF GROWTH ACROSS MEDIA, ENTERTAINMENT AND COMMERCE

New Capital Will Fuel Digital Media Expansion, Original Content and IP, Live Competition, Commerce and Strategic Growth

PONTE VEDRA BEACH, Fla., Oct. 5, 2026 /PRNewswire/ -- Pro Shop, the innovative media platform connecting golf with mainstream culture, today announced the closing of a $24 million Series B financing round led by Arthur M. Blank Sports and Entertainment (AMBSE). The round also welcomes new investors Causeway Media Partners and Ares Sports, Media and Entertainment funds, alongside returning investors including PGA Tour, Powerhouse Capital, and Phoenix Capital Ventures.

Pro Shop will use the new capital to deepen its investment in digital media and original programming, including new talent-led franchises, premium live events and competition formats, and programming designed for social-first audiences. The funding will also support the continued expansion of Pro Shop's owned-and-operated media brands and commerce businesses, as well as strategic acquisitions and partnerships across golf, media, and technology.

"When we launched Pro Shop, the thesis was that golf was entering a new era, one where fans were discovering and engaging with the game across more platforms, formats and communities than ever before," said Chad Mumm, Co-Founder and President of Pro Shop. "The last two years have only reinforced that belief. We've deliberately built Pro Shop to meet modern golf fans wherever they are and give them more ways into the game. This investment allows us to keep building on that vision, backing great talent, creating new formats, and expanding the experiences that connect golf to the broader culture."

In just over two years, Pro Shop has grown into a multi-platform media, entertainment and commerce company spanning premium film and television, digital and creator-led programming, live competition, community and consumer brands. That growth has mirrored golf's broader cultural expansion, as younger and more digital-first audiences increasingly engage with the game across streaming, creators, social platforms, alternative competition, fashion, equipment and lifestyle. Today, Pro Shop reaches more than 35 million unique users across its portfolio and has doubled revenue year over year.

"Golf is now America's largest-growing sport, and as its popularity rises, we're seeing firsthand how people are discovering and engaging with the game in new ways," said Troy Rice, CEO of PGA TOUR Superstore, an AMBSE company, who joins Pro Shop's board as part of AMBSE's lead investment in the Series B round. "From in-home simulators to listening to music while playing, golf entertainment venues and social platforms, these experiences are translating to more people picking up a club and playing on the course. Our investment in Pro Shop extends the ways we connect with golfers and fans through the programming they will produce."

"Pro Shop has demonstrated a strong ability to connect with fans through compelling storytelling, innovative formats and new platforms, as well as being a key production partner of PGA Tour Studios" said Chris Wandell, PGA Tour SVP, Media & Licensing, and Pro Shop Board member. "We have seen firsthand the creativity and ambition the team brings to everything they do and are excited to support the next phase of what they're building."

Through Pro Shop Studios, the company has brought golf to mainstream entertainment audiences as producer of Netflix's Full Swing and co-producer of Happy Gilmore 2 and The Hawk, while expanding into premium live competition through the PGA Tour's Creator Classic and the revival of The Skins Game, which returned in November 2025 after a 17-year hiatus as part of Prime Video's Black Friday sports lineup.

The broader Pro Shop portfolio also includes GolfWRX, trusted destination for golf equipment coverage, news and community forums which was acquired by Pro Shop in 2025; Sugarloaf Social Club, the lifestyle and commerce brand rooted in independent golf culture; and Paige Co., Pro Shop's long-term media and consumer venture with leading golf creator Paige Spiranac.

The Series B follows Pro Shop's $20 million Series A in 2024, led by Powerhouse Capital with participation from the PGA Tour, EP Golf Ventures, Marquee Ventures, Gametime Capital, Phoenix Capital Ventures and other investors across golf, entertainment and finance. Gunderson Dettmer served as legal counsel to Pro Shop.

About Pro Shop:

Pro Shop is a media, entertainment and commerce platform that connects golf with mainstream culture. The company was founded in 2023 by veteran media executives with extensive backgrounds in golf and entertainment, Chad Mumm and Mark Olsen from Vox Media, Joe Purzycki from Puck, and David Miller from PGA Tour. Pro Shop operates Pro Shop Studios, its entertainment division that produces Full Swing, co-produced Happy Gilmore 2 for Netflix; Skratch, a digital-first content hub creating premium programming at the intersection of golf, lifestyle and culture; GolfWRX, the internet's trusted destination for golf news, gear reviews and community forums; Sugarloaf Social Club, a bespoke golf lifestyle and commerce brand; and Paige Co., its long-term media and consumer joint venture with Paige Spiranac.

About Arthur M. Blank Sports and Entertainment:

AMB Sports and Entertainment is part of the Blank Family of Businesses comprised of the National Football League's Atlanta Falcons, Major League Soccer's Atlanta United FC, Atlanta City FC of the National Women's Soccer League, Mercedes-Benz Stadium, Atlanta Drive GC of TGL and WTGL, and PGA TOUR Superstore. 

For inquiries, contact Pro Shop at [email protected]

SOURCE Pro Shop

Share this article

DALLAS, Oct. 5, 2026 /PRNewswire/ -- ICAT Logistics (ICAT), a specialist in high-value, time-critical freight, today announced Jonathan Stein as Global Vice President of Sports and Live Events, a newly created role focused on expanding ICAT's presence in broadcast production, live-events and sports.

Stein joins ICAT after 29 years in live broadcast, most recently leading sales for the Specialty Capture division of NEP, one of the world's largest broadcast services providers.

"I was a client for 29 years, so I've heard every excuse when it comes to logistics and the delays that can come with moving time-sensitive goods," said Stein. "The gear either makes air or it doesn't, and once it doesn't, the excuse has no value to anybody. What I want is for every client to feel like they are the only account we have. That sounds like a slogan until you've spent three decades noticing its absence."

Stein began his career at Fletcher Chicago in 1997, where he helped bring to market camera systems that have since become integral to live sports production, including the Above-The-Rim camera systems and high frame rate pylon cameras used for goal-line coverage. He went on to sell those technologies to clients like ESPN, CBS, FOX, NBC, Turner Sports, and many others — where the success of every production depended on equipment arriving at precisely the right place and time.

Broadcast freight operates within some of the most demanding timelines in the live-events industry. A crew building an Above-The-Rim camera, for example, may need court access before practice begins. Miss that window, and the camera angle may not exist for the broadcast—creating potential financial consequences for advertisers, production companies, teams and other stakeholders.

Stein's first priority at ICAT will be establishing a more proactive communication model for customers, one of the first changes he expects clients to experience.

"Jonathan has worked alongside the industry's leading networks and production companies throughout his career, and he understands the pressures they face better than anyone," said Brad Stogner, CEO, ICAT Logistics. "As live production expands across broadcasters and streaming platforms, his experience positions ICAT to meet that growth with the precision and responsiveness our customers expect."

Live-event logistics has traditionally operated reactively. Stein's standard is different: customers should hear from ICAT before there is a reason to ask, whether the news is good or bad.

The production market Stein is entering has expanded well beyond traditional broadcast networks. Amazon now carries major NFL and NBA programming, Netflix has expanded into live sports, and streaming platforms increasingly produce live events alongside traditional broadcasters such as CBS, Turner and ESPN. Fragmented rights holders mean more concurrent productions and more situations in which a single delayed shipment can affect an entire production.

Stein's focus will be helping ICAT build a logistics model around the realities of live production and sport: proactive communication, accountability and an understanding that when the equipment has to be there, "close" isn't close enough.

For more on ICAT Logistics and its specialized logistics services, visit icatlogistics.com.

About ICAT Logistics

ICAT is the world's leading specialized logistics company, delivering customized solutions and deep vertical expertise to industries where failure is not an option. With 65 offices and operating capabilities in 190 countries, ICAT serves customers across Live Events, Luxury, Technology, Defense & Aerospace, Life Sciences, and Financial Institutions—sectors defined by uncompromising performance standards. ICAT's proprietary, AI-powered technology platform provides end-to-end visibility and predictive intelligence, enabling precise execution for the most demanding operations.

Media Contact:

Tyler Thornton

LeadCoverage

[email protected] 

SOURCE ICAT Logistics, Inc.

Share this article

Through strategic partnerships with Say Yes Buffalo, Buffalo Prep and BISON Children's Scholarship Fund, Rich's deepens investment in Western New York

BUFFALO, N.Y., Oct. 5, 2026 /PRNewswire/ -- Rich Family Foundation, the philanthropic arm of Rich Products, today announced the commitment of more than $2 million in philanthropic support for educational opportunities across Western New York through partnerships with Say Yes Buffalo, Buffalo Prep, and the BISON Children's Scholarship Fund. The investment marks the largest education-focused commitment in Rich's history and reflects the company's belief that one of the most meaningful ways to strengthen the future of Buffalo is by investing in its next generation.

"Buffalo has been Rich's home for more than 80 years, and we believe one of the best ways to invest in its future is by investing in its young people," said Ted Rich, chief growth officer, Rich Products. "Say Yes Buffalo, Buffalo Prep and the BISON Children's Scholarship Fund are opening doors that can change the trajectory of a student's life. By supporting these organizations, we're helping create opportunities for the next generation of leaders who will shape the future of Western New York. We're proud to be part of that."

As nonprofits face increasing demands and a challenging funding environment, Rich's commitment provides both immediate and long-term support for three critical organizations that help students and families access educational opportunities and build brighter futures. More than financial contributions, these commitments reflect long-standing partnerships grounded in a shared commitment to help students learn, grow and succeed through volunteerism, mentorship and community engagement.

Investing in Opportunity Across Western New York

Each organization advances a different aspect of educational success. From academic enrichment and college readiness to scholarship assistance, their collective impact helps create stronger pathways for students and families throughout the region to learn, grow and thrive.

Say Yes

Since its launch in 2012, Say Yes Buffalo has helped expand access to higher education and support services for students and families across Western New York, serving more than 20,000 community members annually and helping more than 4,300 students complete college degrees or certificate programs.

Over the next five years, Rich's will invest $1.25 million in Say Yes Buffalo, providing long-term operational support and funding to help students navigate education, stay on track academically and prepare for a career. With 85% of Say Yes Buffalo scholars choosing post-secondary schools in Western New York, the need for sustained support is significant. Rich's funding will ensure students and families continue to have access to these resources for years to come.

"We are extremely grateful for the investments that the Rich Family Foundation and Rich's continue to make in the talented young people of this city," said Say Yes Buffalo CEO David Rust. "Their visionary leadership is helping transform educational outcomes for Buffalo students by fostering a college-going culture and ensuring young people have the support they need to succeed once they arrive on campus. This funding will help more students navigate challenges, remain on track toward their degrees, and ultimately realize their dreams. There is no better investment in Buffalo's future than helping more students cross the finish line to a rewarding career."

This commitment builds on a longstanding relationship between Rich's and Say Yes Buffalo. In 2021, Rich Family Foundation committed $1 million to Say Yes to support programs that provide students with access to education, mentorship and career coaching. Since 2022, Rich's has also partnered with Say Yes and CareerWise Greater Buffalo to provide youth apprenticeships that connect classroom learning with real-world work experience. Rich's currently has two students completing their Say Yes apprenticeship with the company.

Buffalo Prep

For more than 35 years, Buffalo Prep has helped students prepare for academic success through enrichment programming, mentorship, and college preparation. Serving 750 scholars and alumni annually, Buffalo Prep has a 100% graduation rate, and over the last 10 years, 84% of high school Prep graduates have earned or are on track to earn a bachelor's degree.

To advance Buffalo Prep's mission, Rich's will invest $750,000 over the next five years to support academic enrichment programs and the Illuminate the Future Fund, helping strengthen opportunities for current and future students.

"We're incredibly grateful to Rich Products and the Rich Family Foundation for their generosity and continued support of Buffalo Prep," said David Johnson, executive director, Buffalo Prep. "Their longstanding commitment to our scholars and our community helps us expand educational access and opportunity for young people across Western New York and provide the programs and experiences that help them thrive. We're proud and grateful to have their continued partnership in this work."

BISON Children's Scholarship Fund

Founded in 1995, the BISON Children's Scholarship Fund helps low-income families access educational opportunities through K-12 tuition assistance and scholarship support across Western New York. Since its founding, the organization has awarded 46,000 scholarships, including support for 1,800 elementary and high school students in the 2026-27 school year.

To help sustain BISON's efforts, Rich's will provide $50,000 in scholarship funding over the next two years, helping more students access the educational opportunities, resources and experiences that can shape their future success.

"Rich Products' commitment to BISON is an investment in the future of Western New York," said Clara Moran, executive director, BISON Children's Scholarship Fund. "At BISON, we believe that where a child comes from should never determine where their education can take them. This generous support will help us provide more students with access to high-quality educational opportunities and give families the resources they need to choose the best educational path for their children. We are incredibly grateful to Rich Products for recognizing the power of education and for partnering with us to help more students thrive."

Together, these investments reflect Rich's longstanding belief that strengthening Buffalo's future begins with creating opportunities for the next generation.

MEET RICH'S

Rich's, also known as Rich Products Corporation, is a family-owned food company dedicated to inspiring possibilities. From cakes and icings to pizza, appetizers and specialty toppings, our products are used in homes, restaurants and bakeries around the world. Beyond great food, our customers also gain insights to help them stay competitive, no matter their size. Our portfolio includes creative solutions geared at helping food industry professionals compete in foodservice, retail, in-store bakery, deli, and prepared foods among others. Working in 100 locations globally, with annual sales exceeding $5.8 billion, Rich's is a global leader with a focus on everything that families make possible.

Rich's®—Infinite Possibilities. One Family.

About Say Yes Buffalo

Say Yes Buffalo's mission is to advance economic mobility for Buffalo students through cradle-to-career supports and a postsecondary tuition scholarship promise. Launched in 2012, the Say Yes Buffalo partnership is a community collaboration dedicated to strengthening the city's public school system and increasing high school and postsecondary graduation rates. Our key partners are the Buffalo Public School District, City of Buffalo, Erie County, the Buffalo Teachers Federation, several parent groups, and more than one hundred funders and community-based organizations. More information at SayYesBuffalo.org.

About Buffalo Prep

Buffalo Prep is a nonprofit organization that works to expand educational access and opportunity for students across Western New York. Since 1989, Buffalo Prep has provided academic enrichment, college preparation and ongoing support to scholars from middle school through college and beyond. Today, Buffalo Prep serves more than 750 scholars and alumni each year and has a network of more than 1,100 alumni. Through its programs, Buffalo Prep nurtures scholars' brilliance, supports their growth as leaders and helps ensure they have the resources and opportunities to pursue their goals.

About BISON Children's Scholarship Fund

Founded in 1995, BISON Children's Scholarship Fund is a privately funded 501(c)(3) nonprofit organization dedicated to helping break the cycle of poverty through access to high-quality education. BISON provides tuition assistance to low-income children throughout Western New York, helping families access educational opportunities that may otherwise be out of reach.

For more than 30 years, BISON supporters have helped provide more than 46,000 scholarships, representing over $51.1 million in private investment in Western New York education. Today, BISON partners with 74 schools across the region, supporting students from kindergarten through high school and working alongside families, schools, and community partners to help students reach their full potential.

For more information, visit bisonfund.org.

SOURCE Rich Products Corporation

Share this article

NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The CRE Finance Council (CREFC), the trade association for the commercial real estate finance industry, today released its Third-Quarter 2026 (3Q26) Board of Governors (BOG) Sentiment Index survey results.

The index fell 17.5% to 83.3 from 101.0 in 2Q26, its lowest reading since 3Q23 (82.7), well below the survey's 4Q17 baseline of 100.0 and 34% below the record high of 126.6 set in 4Q24. The decline was broad-based: all nine core questions weakened quarter-over-quarter. The interest rate and economic outlook questions posted the largest declines and together accounted for roughly 30% of the drop, with the remaining seven questions contributing the balance.

Conducted from September 21 – 28, 2026, the survey captured a market adjusting to a 10-year Treasury yield at 5%, roughly a full percentage point above its level a year earlier, even as the federal funds rate sits a quarter point lower. Neutral remained the most common answer on seven of the nine core questions, but the share of negative responses increased on eight of the nine. The survey consists of nine equally weighted core questions and five topical questions, which are not factored into the BOG Index. Ninety-three percent of the BOG responded to the 3Q26 survey.

Demand-side readings weakened further, with borrower demand turning net negative and investor demand losing its positive tilt. Twenty-four percent of respondents expect stronger borrower demand for CRE and multifamily financing over the next 12 months versus 35% expecting weaker demand, the first net-negative reading since 4Q22. Investor demand expectations are evenly split, with 30% expecting more demand and 30% expecting less. Most respondents (65%) still expect unchanged liquidity, but the share expecting a contraction rose to 24% from 5%.

Key Highlights from 3Q26 Index Core Questions:

- Economic Outlook: Economic expectations deteriorated sharply. Sixty-two percent now expect the U.S. economy to perform worse over the next 12 months, up from 24% in 2Q26 and the highest share since 1Q25. Thirty-five percent expect the same and 3% expect improvement, down from 18%.

- Federal Policy: Policy optimism faded rather than reversing. Only 11% expect a positive impact from federal legislative and regulatory actions, down from 26%, while 65% expect a neutral impact (47% in 2Q26). The negative share edged down to 24% from 26%.

- Interest Rate Impact: Rates are the weakest core reading for a second consecutive quarter, and by a wide margin. Ninety-two percent expect mortgage and cap rates to weigh negatively on CRE finance businesses, up from 53% in 2Q26 and the most negative rates reading since 3Q22 (98%). Five percent are neutral and 3% expect a positive impact.

- CRE Fundamentals: Expectations turned net negative for the first time since 1Q25. Thirty percent expect fundamentals (occupancy, rents, NOI) to worsen, up from 11%, while 22% expect improvement (37% in 2Q26) and 49% expect no change.

- Transaction Activity: Investor demand expectations are no longer net positive for the first time since 2Q23. Thirty percent expect increased demand for CRE and multifamily assets over the next 12 months, down from 42%, while 30% expect less demand (11% in 2Q26) and 41% expect no change.

- Financing Demand: Borrower demand expectations turned net negative for the first time since 4Q22. Twenty-four percent expect increased demand for CRE and multifamily financing, down from 45%, while 35% expect less demand (13% in 2Q26) and 41% expect no change.

- Market Liquidity: The negative tail widened. Sixty-five percent expect no change in CRE debt market liquidity (71% in 2Q26), while 24% expect a contraction, up from 5%, and 11% expect improvement, down from 24%.

- CMBS and CRE CLO Outlook: Views turned net negative. Thirty-two percent expect CMBS and CRE CLO demand and spread trends to weigh on performance, up from 13% in 2Q26, while 22% expect a positive impact (37% in 2Q26) and 46% are neutral.

- Overall Industry Sentiment: The negative share nearly quintupled. Thirty-eight percent are negative on CRE finance businesses over the next 12 months, up from 8% in 2Q26 and the largest negative share since 1Q25, while 51% are neutral (68%) and 11% are positive (24%).

Additional Topical Insights:

This quarter's topical questions focused on the rate path and its consequences for values, credit terms, delinquency and the newest large CMBS collateral type, data centers.

Asked where the 10-year Treasury yield, at 5.00% on September 18, 2026, will close on December 31, 2026, 78% of respondents expect 5.00% or higher. The most common answer was 5.00% to 5.24% (41%), followed by 5.25% to 5.49% (30%) and 5.50% or higher (8%). Sixteen percent expect 4.75% to 4.99% and 5% expect 4.50% to 4.74%. No respondent expects a yield below 4.50%.

On U.S. CRE property prices, which were up 0.2% year over year through July 2026 according to MSCI, 46% expect declines over the next 12 months (38% a fall of 1% to 5%; 8% a fall of more than 5%). Thirty percent expect prices to change by less than 1% in either direction, and 24% expect a rise of 1% to 5%. No respondent expects prices to rise more than 5%.

On credit terms for new CRE loans, such as leverage, interest-only periods and lender protections, 38% expect tightening over the next 12 months (8% significantly; 30% modestly), while 43% expect terms to stay about the same and 19% expect modest loosening. No respondent expects significant loosening.

With the CMBS delinquency rate, including conduit and SASB loans, at 7.85% in August 2026 according to Trepp, 61% of respondents expect the rate to be 8.00% or higher on December 31, 2026, including 19% who expect 8.50% or higher. Thirty-six percent expect 7.50% to 7.99%, and 3% expect the rate to fall below 7.50%.

Asked how spreads on AAA-rated data center CMBS, which paid about 165 basis points over benchmark rates in mid-September 2026 compared with 85 to 120 basis points for other property types according to BofA Global Research, will change over the next 12 months, 41% expect widening (27% modestly; 14% significantly), 38% expect little change, and 22% expect modest tightening. No respondent expects significant tightening.

Open-ended commentary shifted from the regulatory capital and credit-structure themes of 2Q26 to the long end of the Treasury curve. Respondents cited fiscal deficits, record Treasury issuance and persistent inflation, including energy and diesel costs, as forces that could keep long-term borrowing costs elevated even if short-term rates ease, with refinancing risk, CMBS spread widening and pricing pressure on office and multifamily as the expected consequences. Comments pointed to both continued refinancing demand as 2021–2022 and 2017 loan vintages mature and rising distress, particularly in office. Data center capital needs and political uncertainty ahead of the midterm elections also featured. Not all commentary was negative; respondents also pointed to continued CRE CLO growth and rising sales volume as owners accept current values.

Raj Aidasani, Managing Director, CREFC, commented:

"This is the most negative our board has been in three years. Rates remain the clearest concern: 92% expect mortgage and cap rates to weigh on CRE finance businesses over the next year, the highest share since the third quarter of 2022. But the decline runs well beyond rates. All nine core questions weakened, and the negative share rose on eight of them. Our members' concerns now extend past the next Fed decision to inflation, fiscal deficits and the outlook for long-term borrowing costs. The number to watch from here is the economy: 62% expect it to weaken over the next 12 months. If that view proves right, weaker rents and cash flow would compound the strain on borrowers already facing higher rates and maturing loans."

About CREFC and the Board of Governors Sentiment Index:

The CRE Finance Council (CREFC) is the trade association for the over $6 trillion commercial real estate finance industry with a membership that includes more than 400 companies and 19,000 individuals. For over 30 years, CREFC has promoted liquidity, transparency, and efficiency in the commercial real estate finance markets, acting as a legislative and regulatory advocate for the industry, playing a vital role in setting market standards and best practices, and providing education for market participants.

The Board of Governors consists of senior executives representing every sector of the commercial real estate lending and mortgage-related debt investing markets, including balance-sheet and securitized lenders, loan and bond investors, mortgage bankers, private equity firms, loan servicers, rating agencies, attorneys, accountants, and others.

CREFC's BOG Sentiment Index, launched in 2017, tracks quarterly shifts in commercial real estate finance sentiment through nine equally weighted core questions, supplemented by topical questions that are not factored into the index. Blank responses are excluded from question denominators, and percentages may not sum to 100% due to rounding. The 3Q26 survey achieved a 93% response rate with 37 of 40 BOG members participating.

For more information about the 3Q26 BOG Sentiment Index and the full survey results, please click here or contact Raj Aidasani at [email protected].

SOURCE CRE Finance Council

Share this article

Net Loss Narrowed 57.0% and Operating Cash Flow Turned Positive; Company Also Received an Additional 180-Day Nasdaq Compliance Period

BEIJING, Oct. 5, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (Nasdaq: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic intelligence and AI-powered multimodal and agent-based digital solutions, today announced its financial results for the fiscal year ended June 30, 2026. Additional details will be available in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission.

Fiscal Year 2026 Financial Highlights

- Revenue: Approximately $40.70 million, compared with approximately $71.62 million in fiscal 2025, representing a decrease of 43.17%. The decline primarily reflected the Company's deliberate reduction of certain standardized, lower-margin AI multimodal, traffic-related and other digital-service activities as part of an active business-mix optimization strategy.

- Gross Profit: Approximately $4.16 million, compared with approximately $2.44 million in fiscal 2025, representing an increase of 70.09%, despite the decline in overall revenue.

- Gross Margin: Increased to 10.21% from 3.41% in fiscal 2025, an improvement of approximately 6.8 percentage points, primarily reflecting a reduced contribution from lower-margin standardized services and a greater relative contribution from customized solutions, acoustic-related products and services, and other activities.

- Cost of Revenues: Decreased approximately 47.2% year-over-year, at a rate greater than the 43.17% decrease in revenue, contributing to the significant improvement in gross profit and gross margin.

- Operating Expenses: Decreased approximately 15.0% to $6.46 million from approximately $7.60 million in fiscal 2025. Selling expenses declined approximately 38.5%, while general and administrative expenses declined approximately 43.1%.

- Research and Development: Increased approximately 180.3% to $2.57 million from approximately $0.91 million in fiscal 2025, reflecting continued investment in acoustic intelligence, NeuroVibe, biofeedback and brain-computer-interface-related technologies, acoustic signal enhancement, product engineering, AI multimodal perception and AI-agent technologies.

- Operating Loss: Narrowed to approximately $2.30 million from approximately $5.15 million in fiscal 2025, representing an improvement of approximately 55.3%.

- Net Loss Attributable to the Company: Narrowed to approximately $2.19 million from approximately $5.09 million in fiscal 2025, representing an improvement of approximately 57.0%.

- Operating Cash Flow: Net cash provided by operating activities was approximately $1.98 million, compared with net cash used in operating activities of approximately $2.37 million in fiscal 2025, representing a year-over-year improvement of approximately $4.35 million.

Management Commentary

Ms. Zhixin Liu, Chief Executive Officer of Datasea, commented:

"Fiscal 2026 was an important year in the evolution of Datasea's business model. Our reported revenue declined during the year. However, we believe revenue alone does not fully reflect the progress made in the underlying quality of our business. Cost of revenues declined faster than revenue, gross profit increased approximately 70%, and gross margin improved from 3.41% to 10.21%. These results reflect the financial impact of our efforts to improve our business mix and focus more closely on profitability and sustainable value creation."

"We also continued to improve operating efficiency. Selling and general and administrative expenses declined substantially, while we simultaneously increased research and development spending by approximately 180%. This reflects an important shift in how we allocate capital and operating resources — reducing lower-efficiency expenditures while continuing to invest aggressively in technologies and products that we believe can support Datasea's long-term growth."

"Importantly, these changes translated into a meaningful improvement in our bottom line. Operating loss narrowed by approximately 55%, net loss narrowed by approximately 57%, and operating cash flow turned positive for the fiscal year. While we have not yet reached profitability, we believe the significant narrowing of losses, together with higher gross margins and improved operating cash flow, represents meaningful progress toward a more balanced and sustainable earnings model."

The Company also recently received an additional 180-calendar-day compliance period from Nasdaq to regain compliance with the minimum bid price requirement until March 22, 2027. The additional compliance period provides the Company with further time to regain compliance in accordance with Nasdaq Listing Rule 5550(a)(2).

Investment in Technology and Future Growth

Rather than broadly reducing investment in response to lower revenue, Datasea continued to increase resources allocated to core technology development.

Research and development expenses increased to approximately $2.57 million in fiscal 2026, compared with approximately $0.91 million in fiscal 2025.

The Company's R&D activities during the year focused principally on acoustic intelligence, NeuroVibe and related biofeedback and brain-computer-interface technologies, acoustic signal enhancement, product engineering, AI multimodal perception, and AI-agent technologies and platform capabilities.

Datasea believes this resource allocation supports its longer-term strategy of transitioning from volume-driven digital services toward a portfolio with greater technology differentiation, stronger product capabilities and improved value-added potential.

Business Outlook

Looking ahead, Datasea intends to continue pursuing disciplined growth across its two principal technology platforms:

- Acoustic Intelligence: Continue product development, engineering, regulatory advancement and commercialization of acoustic healthcare and acoustic medical applications, including the NeuroVibe platform, while expanding the potential application of the Company's acoustic technologies across additional healthcare and industry scenarios.

- AI Multimodal and AI-Agent Solutions: Continue shifting toward higher-value customized digital solutions and AI-agent services designed to support enterprise customer operations, marketing execution, customer interaction, data analysis and other recurring business processes.

The Company believes fiscal 2026 represents an important stage in its transition toward a more technology-driven, higher-margin and operationally efficient business model. The pace and ultimate success of this transition will depend on customer adoption, commercialization progress, operating costs, market conditions and the Company's ability to convert its developing technologies and products into sustainable revenue and cash flow.

About Datasea Intelligent Technology Ltd.

Datasea Intelligent Technology Ltd. (Nasdaq: DTSS) is a technology company focused on acoustic intelligence and AI-powered multimodal and agent-based digital solutions.

The Company is developing and commercializing acoustic technologies across healthcare, medical and other application scenarios while continuing to advance AI multimodal technologies and AI-agent solutions designed to support enterprise digital operations and customer-service applications.

Through continued investment in technology development, product engineering and commercialization, Datasea seeks to build scalable technology platforms and higher-value products and services for customers in China, the United States and other markets.

For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements involving risks and uncertainties, including but not limited to statements regarding the commercialization progress of the Company's products in target markets, compliance with regulatory obligations, market validation results, product iteration plans, channel development, application expansion and future business prospects. Actual results may differ materially from those expressed or implied by these forward-looking statements. Investors should not place undue reliance on these statements. Further information regarding risks and uncertainties is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Datasea Investor Relations

Email:  [email protected] 

[email protected] 

Precept Investor Relations LLC

David Rudnick

+1 646-694-8538

[email protected]

SOURCE Datasea Inc.

Share this article

DELRAY BEACH, Fla., Oct. 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the AI in Protein Engineering Market is projected to reach USD 3.82 billion by 2031 from USD 1.44 billion in 2026, at a CAGR of 21.6% during the forecast period.

Browse 350 market data Tables and 50 Figures spread through 450 Pages and in-depth TOC on "AI in Protein Engineering Market - Global Forecast to 2031"

AI in Protein Engineering Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 1.44 billion

- 2031 Projected Market Size: USD 3.82 billion

- CAGR (2026–2031): 21.6%

AI in Protein Engineering Market Trends & Insights:

- North America dominates the AI in protein engineering market, with a share of 48.6% in 2025.

- By offering, software/platforms dominate the market with a share of 75.4% in 2025.

- By protein type, the miniproteins segment is expected to register the highest CAGR of 23.7% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=27766714

Market expansion of AI in protein engineering is being propelled by the increasing complexity of protein discovery and optimization, growing AI investment, and the need for faster, more cost-efficient R&D. AI technologies, including machine learning and deep learning, protein language models, generative AI, and structure-based AI, are increasingly applied to protein discovery, de novo design, sequence optimization, structure prediction, and developability assessment. According to a 2025 Benchling survey of ~100 biotech and pharmaceutical organizations, 55% allocated at least 11% of their R&D technology budgets to AI, including 28% allocating 11–20%, 18% allocating 21–35%, and 6% allocating >35%. AI adoption is also expanding, with 48% reporting strategic AI integration and 87% reporting AI agents embedded in workflows, products, or services. AI is also demonstrating productivity gains, with Recursion reporting approximately 330 compounds per program over 17 months, compared with an industry average of 2,500+ compounds over 42 months. Moreover, 88% planned to increase cloud/infrastructure investment, 86% data-platform investment, and 84% AI-platform investment. However, adoption remains constrained by scaling, data, talent, computational, and validation challenges, with only 22% successfully scaling AI and 9% achieving significant returns. These trends are expected to accelerate adoption of AI-powered protein engineering platforms while organizations seek to reduce experimental iterations and improve R&D productivity.

By application, the next-generation biologics segment is expected to register the fastest growth rate during the forecast period.

By application, next-generation biologics is expected to be the fastest-growing segment of the AI in protein engineering market. This segment's growth is driven by increasing demand for novel, more effective protein therapeutics; the rising complexity of biologic molecules; and growing adoption of AI for de novo protein design, antibody discovery and optimization, enzyme engineering, and protein stability and developability optimization. Pharmaceutical and biotechnology companies are increasingly leveraging AI-powered protein engineering platforms to explore large protein sequence spaces, identify promising candidates, and accelerate the design–build–test cycle. Additionally, advances in protein language models and generative AI are enabling the design of novel proteins with desired structural and functional properties, further supporting adoption in next-generation biologics. As investment in innovative biologic modalities continues to increase, demand for AI-enabled protein design and optimization solutions is expected to accelerate, helping organizations reduce experimental iterations, improve candidate selection, and shorten development timelines.

By AI tool, generative AI accounted for the largest share of the AI in protein engineering market in 2025.

By AI tool, generative AI accounted for the largest share of the AI in protein engineering market in 2025. This dominance can be attributed to the growing adoption of generative AI for de novo protein design, antibody generation and optimization, enzyme engineering, and protein sequence generation. Generative AI models enable researchers to explore vast protein sequence spaces and design novel proteins with desired structural and functional properties, reducing reliance on conventional trial-and-error approaches. Furthermore, the growing availability of large-scale protein datasets, advances in foundation models and generative architectures, and integration with high-throughput experimental workflows are improving the scalability and efficiency of AI-driven protein engineering. The growing use of generative AI by pharmaceutical and biotechnology companies to accelerate protein discovery and optimize therapeutic candidates is expected to further strengthen its market leadership.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=27766714

The Asia Pacific is expected to be the fastest-growing market during the forecast period.

The AI in protein engineering market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific is projected to be the fastest-growing regional market for AI in protein engineering, driven by increasing investments in biotechnology and pharmaceutical R&D, expanding AI and computational biology capabilities, and growing adoption of AI-enabled approaches for protein discovery, design, and optimization. Countries such as China, India, Japan, South Korea, and Australia are strengthening their life sciences and AI ecosystems through government-backed research programs, expanding biopharmaceutical manufacturing, and investments in advanced computing and biotechnology infrastructure. China invested about RMB 3.63 trillion (USD ~500 billion) in R&D in 2024, an 8.9% year-over-year increase, with basic research spending up 10.7%, supporting the development of advanced computational and life sciences capabilities. India's bioeconomy reached USD 165.7 billion in 2024, more than 16-fold higher than in 2014, while the government continues to promote biotechnology innovation through initiatives such as BioE3 and increased support for biotech startups. Japan also recorded JPY 22.05 trillion in total R&D expenditure in FY2023, with pharmaceutical R&D expenditure reaching JPY 1.54 trillion, up 7.6%, highlighting the region's strong pharmaceutical research base. These investments are creating favorable conditions for adopting protein language models, generative AI, structure-based AI, machine learning, and deep learning for applications including de novo protein design, antibody discovery and optimization, enzyme engineering, and protein stability prediction. Furthermore, the growing presence of pharmaceutical companies, biotech startups, CROs, academic research institutes, and AI-protein engineering companies across the region is expected to accelerate the deployment of AI-enabled protein engineering platforms and strengthen Asia Pacific's position as the fastest-growing regional market.

Key Players

Leading players in the AI in Protein Engineering companies include Schrödinger, Inc. (US), XtalPi (China), Dassault Systèmes (France), NVIDIA Corporation (US), Generate: Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=27766714

AI in Protein Engineering Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The AI in protein engineering market is witnessing increasing investment activity, supported by growing investor and pharmaceutical interest in generative AI, protein foundation models, and de novo protein design. In 2024, EvolutionaryScale raised USD 142 million to develop AI models that generate novel proteins, while in February 2025, Latent Labs secured USD 50 million to advance generative AI models for protein design. Investment momentum continued in November 2025, when AI Proteins raised USD 41.5 million in Series A financing to advance AI-designed de novo miniprotein therapeutics. The funding environment is further supported by growing pharmaceutical-industry collaboration, with 120 AI-based target and drug discovery deals recorded in 2025, representing 23% of the 513 such deals tracked since 2017; total potential deal value reached USD 29.7 billion, with nearly USD 800 million committed upfront. These investments and strategic collaborations highlight increasing confidence in AI-enabled protein design and are expected to support the development of generative protein design, antibody engineering, enzyme optimization, and next-generation biologics.

Revenue Shift Context

The market is shifting toward AI-driven, computationally enabled platforms that accelerate protein discovery, design, and optimization. The AI in protein engineering market is projected to rise from USD 1.44 billion in 2026 to USD 3.82 billion by 2031, at a CAGR of 21.6%, with much of this growth concentrated in AI-powered protein design, generative protein engineering, protein language models, antibody discovery and optimization, enzyme engineering, and protein stability and developability solutions. Meanwhile, software/platforms accounted for 75.4% of the market in 2025, highlighting strong adoption of AI-enabled platforms, while emerging areas such as generative AI, de novo protein design, protein language models, and AI-driven optimization are capturing a rising share of new spending.

Mergers and Acquisitions

Mergers and acquisitions in the AI in protein engineering market are gaining momentum, with companies increasingly targeting AI-driven protein design, computational biology, and generative AI capabilities.

The SERD market is expected to grow significantly due to factors like improved diagnosis, treatment advancements, demographics, increased awareness, and supportive regulations in the 7MM. Additionally, the recent approvals of SERD drugs such as AstraZeneca's ETCAMAH (camizestrant) and pipeline activity of emerging therapies including Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), and others are expected to fuel the market of SERD by 2036.

LAS VEGAS, Oct. 5, 2026 /PRNewswire/ -- DelveInsight's SERD Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging SERD drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the SERD Market Report

- The total SERD market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest SERD market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- The report provides the total potential number of patients in the indications, such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others.

- HR+/HER2- breast cancer is one of the leading target indication for use of SERDs in the 7MM with total cases of nearly 485,000 in 2025, which is expected to increase by 2036 in the 7MM.

- Leading SERD companies, such as Olema Pharmaceuticals, Roche, EnhancedBio, Zenopharm, Inventis Bio, Atossa Therapeutics, Hengrui Medicine, Simcere, Kind Pharmaceuticals, and others, are developing novel SERD drugs that can be available in the SERD market in the coming years.

- Some of the key SERD drugs in clinical trials include Palazestrant, Giredestrant, Borestrant, D-0502, (Z)-Endoxifen, HRS-8080, SIM0270, AND019, and others.

Discover what patient populations may benefit most from treatment with oral SERDs @ https://www.delveinsight.com/report-store/serd-market-forecast

Key Factors Driving the SERD Market

- Rising Prevalence of Hormone Receptor-Positive Breast Cancer: The growing incidence of estrogen receptor-positive (ER+) breast cancer is increasing the demand for effective endocrine therapies. SERDs directly target estrogen receptor signaling, creating a strong addressable patient population.

- Increasing Resistance to Existing Endocrine Therapies: Acquired resistance to aromatase inhibitors and selective estrogen receptor modulators remains a major treatment challenge. SERDs offer a differentiated approach by binding to and promoting degradation of the estrogen receptor, potentially addressing resistance mechanisms.

- Growing Adoption of Oral SERDs: The development of oral SERDs is improving treatment convenience compared with injectable or intramuscular endocrine therapies. The recent approval of AstraZeneca's ETCAMAH (camizestrant) is further strengthening the shift toward oral SERDs in hormone receptor-positive, HER2-negative advanced breast cancer.

- Expansion of SERDs Into Earlier Lines of Therapy: Clinical development is increasingly evaluating SERDs in earlier treatment settings and in combination with other targeted therapies. Successful results could expand their use beyond heavily pretreated or advanced disease.

- Combination With Targeted Cancer Therapies: SERDs are being investigated alongside CDK4/6, PI3K, AKT, and other targeted inhibitors to improve treatment outcomes. These combination strategies are broadening the potential role of SERDs within precision oncology.

- Launch of Emerging SERD Drugs: The dynamics of the SERD market are expected to change in the coming years due to the launch of emerging therapies such as Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the SERD market is indeed growing, with camizestrant and imlunestrant leading the way. This creates a significant opportunity for other players like Roche, which is developing giredestrant, an upcoming SERD.

SERD Market Analysis

- Elacestrant became the first oral SERD to receive regulatory approval in the modern SERD era, introducing a new treatment option for patients with ESR1-mutated, ER+/HER2− advanced or metastatic breast cancer (mBC) following endocrine therapy.

- The therapeutic class is now entering a more competitive phase with the recent approvals of imlunestrant and AstraZeneca's camizestrant, further expanding the SERD treatment landscape and its commercial potential.

- The SERD landscape is shifting from injectable fulvestrant toward oral, next-generation estrogen receptor degraders, reflecting the need for more convenient endocrine treatment options and improved management of endocrine-resistant ER+/HER2− breast cancer.

- Recent market growth has been driven by elacestrant and imlunestrant, both of which are positioned for ESR1-mutated advanced or metastatic disease.

- A major challenge for SERDs remains the ability to demonstrate meaningful clinical benefits over established endocrine therapy and CDK4/6 inhibitor regimens, particularly in earlier lines of treatment.

- Biomarker-based patient selection will therefore be critical, with the identification of emergent ESR1 mutations expected to play an important role in optimizing treatment efficacy and supporting broader adoption of SERDs.

- Despite recent regulatory advances, the SERD class continues to face substantial late-stage development risk.

- Amcenestrant and giredestrant failed to meet their primary endpoints in Phase III trials, while camizestrant did not demonstrate a statistically significant improvement in PFS in SERENA-4.

- These outcomes underscore the difficulty of establishing superiority over established endocrine therapy/CDK4/6 inhibitor combinations.

- The emerging SERD pipeline includes several notable candidates, including giredestrant from Roche, palazestrant from Olema Pharmaceuticals, borestrant from EnhancedBio/Zenopharm, and D-0502 from Inventis Bio, among others.

Learn more about best SERD for ER-positive metastatic breast cancer @ Oral SERD Breast Cancer

SERD Competitive Landscape

Some of the SERD drugs under development include Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Roche's Giredestrant is an investigational selective estrogen receptor degrader (SERD) designed to completely inhibit estrogen receptor signaling while achieving robust receptor occupancy. Estrogen promotes the proliferation of hormone receptor-positive breast cancer cells by binding to estrogen receptors. Giredestrant is currently being investigated across multiple settings, including first-line (1L) ER+/HER2– metastatic breast cancer, 1L ER-positive/HER2-positive breast cancer, 1L endocrine therapy-resistant ER+/HER2– breast cancer, adjuvant ER+ breast cancer, endometrial cancer, and ovarian cancer.

Olema Pharmaceuticals' Palazestrant (OP-1250) is a novel, orally administered small molecule that combines complete estrogen receptor antagonist (CERAN) and SERD activities. It is currently being evaluated in patients with recurrent, locally advanced, or metastatic ER+/HER2– breast cancer. The U.S. FDA has granted Fast Track designation (FTD) to palazestrant for the treatment of ER+/HER2– metastatic breast cancer. The therapy is being assessed as a monotherapy in the ongoing pivotal Phase III OPERA-01 trial and in combination with ribociclib in the pivotal Phase III OPERA-02 trial.

EnhancedBio/Zenopharm's Borestrant is a first-in-class, small-molecule, steroidal oral SERD under clinical development for patients with ER+/HER2– locally advanced or metastatic breast cancer. It is currently being evaluated in a Phase I/II clinical trial in patients with ER+/HER2– locally advanced or metastatic breast cancer.

The anticipated launch of these emerging therapies are poised to transform the SERD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SERD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about oral SERD, visit @ Oral SERD Drugs

Recent Developments in the SERD Market

- In September 2026, AstraZeneca's camizestrant in combination with CDK 4/6 inhibitor had been approved in the US for the treatment of adult patients with HR+, HER2–, locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1L endocrine therapy

- In June 2026, Roche announced that the US FDA had accepted the company's NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER+/HER2–, stage I, II, and III breast cancer.

PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- "I wanted to create a convenient caddy that would assist in maintaining a proper skin care routine," said an inventor, from South Attleboro, Mass., "so I invented the DERMOVA. My design ensures there is specific place for all your skin care products and instructions for how/when to use them."

The invention provides a new caddy/organizer for face and skin care. In doing so, it ensures the user follows a proper skin care routine. As a result, it increases convenience. It also could help solve skin care issues faster and more effectively. The invention features a durable design that is easy to use so it is ideal for the general population.

The original design was submitted to the Boston sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-BKC-965, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp

Share this article